At a glance
- Originator Merck & Co
- Mechanism of Action Cholecystokinin A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Pancreatic disorders
Most Recent Events
- 22 Aug 2001 No-Development-Reported for Pancreatic disorders in USA (Unknown route)
- 04 Aug 1997 New profile
- 04 Aug 1997 Preclinical development for Pancreatic disorders in USA (Unknown route)